Additional file 2 of Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation

Additional file 2: Figure S1. Lymphocyte counts in the BAL fluid of mice from all experimental groups 1 day post-elastase treatment. Figure S2. Immunostaining VEGF-A (A), eNOS (B), and Ki 67 (C) in the lung vasculature of mouse lung of all experimental groups at Pulmonary Hypertension phase. Scale bar:50 uM. Black arrows indicate vessel.